Meta-analysis of dermatological toxicities associated with sorafenib-Reference-Cited by-同舟云学术

Meta-analysis of dermatological toxicities associated with sorafenib

Published:2011-04-20 Issue:4 Volume:36 Page:344-350
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

Zhang L.,Zhou Q.,Ma L.,Wu Z.,Wang Y.

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2230.2011.04060.x/fullpdf

Reference36 articles.

1. BAY43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis;Wilhelm;Cancer Res,2004

2. US Food and Drug Administration Nexavar (sorafenib) prescribing information http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021923s004s005s006s007lbl.pdf

3. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma;Ratain;J Clin Oncol,2006

4. Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial;Escudier;J Clin Oncol,2009

5. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitory Effects of Dioscoreae Rhizoma and Polygalae Radix Mixture Combined with  Sorafenib in Hepatoma Xenografts Model;Pharmacognosy Magazine;2024-08-21

2. Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma;Journal of Hepatocellular Carcinoma;2023-10

3. Sorafenib-Induced Spiny Follicular Hyperkeratosis: A Case Report with Review of Literature;Indian Journal of Medical and Paediatric Oncology;2023-05-12

4. A case of multiple hepatocellular carcinoma experiencing complete responses to sorafenib and atezolizumab–bevacizumab and developing severe, refractory venous congestive cutaneous ulcers on either regimen;Clinical Journal of Gastroenterology;2023-01-09

5. Case Report: Severe rash/desquamation induced by sorafenib in an uHCC patient and its clinical management;Frontiers in Pharmacology;2022-09-13